Claims for Patent: 10,202,357
✉ Email this page to a colleague
Summary for Patent: 10,202,357
Title: | Class of quinolone heterocyclic aromatic molecules for cancer treatment |
Abstract: | The invention is directed to new class of quinolone heterocyclic aromatic molecules (Renotinibs) and their use in the treatment of cancer, in particular, cancer that harbor abnormal human epidermal growth factor receptors (EGFRs). |
Inventor(s): | Wang; Jujun (Plano, TX), Tsao; Allen (Wind Lake, WI), Liu; Xiaomei (Flushing, NY) |
Assignee: | RenoTarget Therapeutics, Inc. (Wind Lake, WI) |
Application Number: | 15/803,478 |
Patent Claims: | 1. A compound having the structure of Formula I: ##STR00013## wherein: R1 is selected from the group consisting of: ##STR00014## where n is 0, 1, 2, 3, or 4; R2 is selected
from the group consisting of: --H, --CH.sub.3, --OCH.sub.3, --NO.sub.2 and a halogen, R3 is selected from the group consisting of: --H, --CH.sub.3, --OCH.sub.3, and a halogen, R4 is selected from the group consisting of: --H, --CH.sub.3, --OCH.sub.3,
--NO.sub.2, and a halogen, R5 is selected from the group consisting of: --H, --CH.sub.3, --OCH.sub.3, and a halogen, R6 is selected from the group consisting of: --H, and a halogen, R7 is selected from the group consisting of: --H, and a halogen, R8 is
selected from the group consisting of: --H, and an ethynyl, and R9 is selected from the group consisting of: --H, and a halogen, or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1, having the structure of Formula II: ##STR00015## wherein R is a halogen, or the pharmaceutically acceptable salt thereof. 3. The compound or the pharmaceutically acceptable salt thereof of claim 2, wherein R is selected from the group consisting of: fluoride, chloride, and bromide. 4. The compound of claim 3, wherein R is a fluoride. 5. The compound of claim 1, having the structure of Formula III: ##STR00016## wherein R is a halogen, or the pharmaceutically acceptable salt thereof. 6. The compound or pharmaceutical acceptable salt thereof of claim 5, wherein R is selected from the group consisting of: fluoride, chloride, bromide, and iodide. 7. A pharmaceutical composition comprising: a compound having the structure of Formula I: ##STR00017## wherein: R1 is selected from the group consisting of: ##STR00018## where n is 0, 1, 2, 3, or 4; R2 is selected from the group consisting of: --H, --CH.sub.3, --OCH.sub.3, and a halogen, R3 is selected from the group consisting of: --H, --CH.sub.3, --OCH.sub.3, and a halogen, R4 is selected from the group consisting of: --H, --CH.sub.3, --OCH.sub.3, --NO.sub.2, and a halogen, R5 is selected from the group consisting of: --H, --CH.sub.3, --OCH.sub.3, and a halogen, R6 is selected from the group consisting of: --H, and a halogen, R7 is selected from the group consisting of: --H, and a halogen, R8 is selected from the group consisting of: --H, and an ethynyl, and R9 is selected from the group consisting of: --H, and a halogen, or a salt thereof; and a pharmaceutically acceptable carrier. 8. The pharmaceutical composition of claim 7, further comprising at least one additional anti-cancer agent selected from the group consisting of: a conventional chemotherapeutic agent, a protein kinase inhibitor, a topoisomerase inhibitor, a mitotic kinesin inhibitor, a histone deacetylase inhibitor, a mTOR inhibitor, a growth factor inhibitor, a growth factor receptor inhibitor, a transcriptional factor inhibitor, an anticancer monoclonal antibody, and glucocorticoid hormones for the simultaneous, separate, or sequential treatment of cancer. 9. The composition of claim 8, wherein the conventional chemotherapeutic agent is selected from the group consisting of: an alkylating agent, an anti-metabolitic agent, an antibiotic, an anti-tubule agent, and an anti-hormonal agent. 10. The composition of claim 8, wherein the conventional chemotherapeutic agent is selected from the group consisting of: mechlorethamine, cyclophosphamide, Busulfan, chlorambucil, leukeran, paraplatin, cisplatin, carboplatin, platinol, Methotrexate (MTX), 6-mercaptopurine (6-MP), cytarabine (Ara-C), floxuridine (FUDR), fluorouracil, hydroxyurea (Hydrea), etoposide (VP16), actinomycin D, bleomycin, mithramycin, daunorubicin, paclitaxel, and its derivatives, vinca and its derivatives, bicalutamide, Flutamide, Tamoxifen, and Megestrol. 11. The composition of claim 8, wherein the protein kinase inhibitor is selected from the group consisting of: inhibitors of cyclin-dependent kinases, tyrosine kinases, phosphoinositide 3-kinase PI3K/AKT, protein kinase C, casein kinases, MAP kinases, and Src kinases. 12. The composition of claim 8, wherein the protein kinase inhibitor is selected from the group consisting of: midostaurin, 7-hydroxystaurosporine, bryostatin 1, perifosine, ilmofosine, Ro 31-8220, Ro 32-0432, GO 6976, ISIS-3521, macrocyclic bis (indolyl) maleimides, AZD9291, and erlotinib. 13. The composition of claim 8, wherein the anticancer monoclonal antibody is selected from the group consisting of: Cetuximab, Herceptin, and Bevacizumab. 14. The composition of claim 8, wherein the glucocorticoid hormone is selected from the group consisting of: dexamethasone, prednisone, prednisolone, metyylprednisolone, and hydrocoritisone. |
Details for Patent 10,202,357
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2036-11-09 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2036-11-09 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | ⤷ Try a Trial | 2036-11-09 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.